Hong Kong and Korean biotech leaders through Stock Connect.
Alteogen Inc. approved a 30% bonus issue, allocating 0.3 new shares per existing share to shareholders of record on 2026-08-06. The company’s shares were temporarily halted on 2026-07-16 following the announcement, and the new shares are scheduled to list on 2026-08-20.
2Q 2026 earnings release on 2026-07-29; analysts forecast a significant profit increase due to the recognition of a large, one-time technology export contract fee. High importance is estimated due to the expected >10% price impact from the revenue surge, forecasted and scheduled.
Q2 2026 earnings release scheduled. Analysts forecast revenue of 1.322 trillion KRW and operating profit of 599.7 billion KRW. High importance is estimated due to the significant growth forecast likely resulting in a >=10% price impact, scheduled.
Partner Johnson & Johnson announced that Q2 2026 global sales of the Leclaza (lazertinib) combination therapy increased by 60.8% year-over-year to $289 million, signaling a rise in royalty income for Yuhan; estimated >5% price impact due to significant revenue growth, expected.
Announced the temporary postponement of the company's planned relocation from the KOSDAQ to the KOSPI market on July 16, 2026, citing shareholder value.
Celltrion received IND approval from the Korean Ministry of Food and Drug Safety on 2026-07-15 to begin a Phase 1 clinical trial for CT-P68. Low importance is estimated as Phase 1 approvals for biosimilars typically result in a price impact of 1-5%.
Announced the expansion of a research service agreement with Pfizer for an oral obesity treatment, increasing the contract value from 1.83B KRW to 2.53B KRW and extending the term to Feb 2028.
Celltrion voluntarily withdrew its European clinical trial plan for 'CT-P51' on 2026-07-14. Low importance is estimated as this strategic decision to align with regulatory trends is expected to have a minimal market impact of 1-5%.